Free tool
FAERS Monitor: Palsonify
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219070 or its brand name (Palsonify, Paltusotine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
238
Serious
36
15% of reports
Hospitalization
24
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea52
- fatigue28
- product dose omission issue28
- nausea27
- abdominal discomfort25
- arthralgia21
- headache21
- abdominal pain16
- abdominal pain upper15
- gastrointestinal disorder14
- off label use14
- therapy interrupted14
- blood glucose increased13
- dizziness13
- incorrect dose administered12
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 2 |
| 2026 | 236 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,921 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| therapy interruptedSignal | 14 | 17.3 | 10.4 | 200 |
| gastrointestinal disorderSignal | 14 | 13.8 | 8.3 | 154 |
| abdominal discomfortSignal | 25 | 13.2 | 9.1 | 271 |
| product dose omission issueSignal | 28 | 8.4 | 5.9 | 178 |
| diarrhoeaSignal | 52 | 7.1 | 5.6 | 276 |
| abdominal pain upperSignal | 15 | 6.4 | 3.9 | 64 |
| blood glucose increasedSignal | 13 | 6.1 | 3.6 | 51 |
| abdominal painSignal | 16 | 6.1 | 3.8 | 64 |
| incorrect dose administeredSignal | 12 | 4.6 | 2.7 | 31 |
| arthralgiaSignal | 21 | 4.5 | 3.0 | 54 |
| fatigueSignal | 28 | 3.2 | 2.2 | 41 |
| nauseaSignal | 27 | 3.0 | 2.1 | 36 |
| headacheSignal | 21 | 3.0 | 2.0 | 26 |
| dizzinessSignal | 13 | 2.3 | 1.4 | 9 |
| off label use | 14 | 1.4 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.